Lille,France – 22nd July 2025– InBrain Pharma, a company specialized in brain infusion of therapeutic agents
targeting neurodegenerative diseases, today announced that it has received financial support from France Parkinson, a French non-profit organization recognized as serving the public interest, to move forward the preparedness of its pivotal Phase III clinical trial. This equity investment in InBrain Pharma marks a major milestone for the company, which is the first in the world to offer personalized cerebral supplementation of dopamine to improve motor function in patients with advanced Parkinson’s disease.
This commitment of France Parkinson towards InBrain Pharma acknowledges the innovativeness of this groundbreaking therapeutic approach for parkinsonian patients consisting in a continuous circadian intracerebroventricular (i.c.v.) infusion of A-dopamine – a dopamine specifically designed for a cerebral use, placed under an anaerobic condition.This therapeutic strategy aims to personalize the cerebral dopamine titration
to compensate for its deficiency. The new therapeutic option in advanced disease stage, based on research conducted at Lille University Hospital and the University of Lille by Professors David Devos and Caroline Moreau – co-founders and scientific advisors of InBrain Pharma – recently showed an outstanding clinical efficacy and an excellent tolerability in the DIVE-I clinical study, which results have been published in Nature Medicine.
“France Parkinson’s support is a powerful signal at a turning point in our project, where rallying stakeholders – especially the patient community – is essential. It also underscores the patients’ strong expectations for game changing therapies that can truly improve daily life and quality of life. We warmly thank France Parkinson for standing behind us ” said Dr. Véronique Foutel, InBrain Pharma CEO.
This new collaboration with France Parkinson will also open up opportunities for InBrain Pharma to further
document the patient reported outcome dimension through its upcoming Phase III trial and afterwards in the real-life setting. Gathering patient feedback on such an innovative therapeutic program is today indispensable and highly valuable, as systematically required by Regulatory Authorities and Health Technology Assessment Bodies.
“FranceParkinson supports innovative players whose projects have the potential to truly change the daily life of people with Parkinson’s disease. InBrain Pharma’s approach perfectly embodies this ambition: it combines scientific excellence, technological innovation, and a clear commitment to improving the quality of life for patients in advanced stages of the disease” emphasized Marie Fuzzati, PhD, Scientific Director of France Parkinson
PressContact: Florence Portejoie // FP2COM // fportejoie@fp2com.fr//+33 6 07 76 82 83
About InBrainPharma
InBrain Pharma is a pioneer in personalized medicine for neurology, developing a circadian intracerebroventricular (i.c.v.) dopamine titration therapy for patients with advanced Parkinson’s disease. Founded in 2018, this biopharmaceutical company holds an exclusive worldwide license from SATT Nord for patents covering this breakthrough therapeutic approach, based on the research of Prof. David Devos and Prof. Caroline Moreau, from the University of Lille, INSERM UMR-S 1172 (Lille Neuroscience & Cognition), and Lille University Hospital.
In May 2025, InBrainPharma secured €1.8 million in funding for its PERCEPAR project as part of France 2030’s “First Factory” initiative, aimed at industrializing the anaerobic production of A-dopamine for Parkinson’s disease. In early July 2025, InBrain Pharma received positive scientific advice from the EMA to move A-dopamine into Phase III trials.
About France Parkinson
France Parkinson is a non-profit organization recognized as serving the public interest. Since 1984, it has been working to inform and support patients and caregivers, train healthcare and social care professionals, promote research, engage public authorities, and raise awareness about Parkinson’s disease. The association currently has 82 local committees and more than 11,000 members.
https://www.franceparkinson.fr
https://soutenir.franceparkinson.fr/donner/
